Dolly the sheep: the demise of biotechnology patents

The US Federal Circuit has recently been called upon to apply the Prometheus and Myriad decisions to a particularly famous project: the creation of Dolly the cloned sheep.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Bioverativ and Bicycle Therapeutics in $10m haemophilia deal

7 September 2017 Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.

Americas

Federal Circuit refuses to review Dolly the sheep ruling

14 August 2014 The US Court of Appeals for the Federal Circuit has refused to grant an en banc review of its ruling that cloned animals made by methods that produced Dolly the sheep cannot be patented, according to Law360.

More on this story

Americas

Bioverativ and Bicycle Therapeutics in $10m haemophilia deal

7 September 2017 Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.

Americas

Federal Circuit refuses to review Dolly the sheep ruling

More on this story

Americas

Bioverativ and Bicycle Therapeutics in $10m haemophilia deal

7 September 2017 Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.

Americas

Federal Circuit refuses to review Dolly the sheep ruling